1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 1:Demographic information of the patients with rRCC proved at surgical resection
Patient Age (yr) Sex Prolactin (μg/L) Presenting Symptom Preop Diagnosis Follow-Up 1 51 Female 33.2 HA Adenoma No recurrence at 6 mo 2 47 Female n/a HA, panhypopituitary RCC Recurrence at 3 yr 3 38 Female 2.7 HA Adenoma No recurrence at 4 yr 4 39 Female 22.4 Enlarging lesion RCC No recurrence at 1 mo 5 30 Female 36.5 Diabetes insipidus, vision changes Adenoma No recurrence at 2 mo 6 72 Female 42.4 Fatigue Adenoma No recurrence at 2 mo 7 33 Female 113.2 Hyperprolactinemia Adenoma No recurrence at 2 mo
Note:—HA indicates headache; Preop, preoperative; n/a, not available.